ViiV Healthcare, a GlaxoSmithKline unit, unveiled data from its trial that showed its injection formula of cabotegravir and rilpivirine as a treatment for HIV was just as effective given bi-monthly as it is administered once a month. The injection not only reduces the treatment frequency but also helps patients who cannot take daily pills.
Experimental HIV injection just as effective administered bi-monthly
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.